European Journal of Inflammation,
Journal Year:
2023,
Volume and Issue:
21
Published: Jan. 30, 2023
Pancreatic
β-cells
produce
and
secrete
insulin
to
maintain
blood
glucose
levels
within
a
narrow
range.
Defects
in
the
function
mass
of
play
significant
role
development
progression
diabetes.
Increased
β-cell
deficiency
apoptosis
are
observed
pancreatic
islets
patients
with
type
2
At
an
early
stage,
adapt
resistance,
their
secretion
increases,
but
they
eventually
become
exhausted,
decreases.
Various
causal
factors,
such
as
high
glucose,
free
fatty
acids,
inflammatory
cytokines,
islet
amyloid
polypeptides,
contribute
impairment
function.
Therefore,
maintenance
is
logical
approach
for
treatment
prevention
In
this
review,
we
provide
overview
these
risk
factors
loss
associated
mechanisms.
A
better
understanding
molecular
mechanisms
underlying
will
opportunity
identify
novel
therapeutic
targets
International Journal of Medical Sciences,
Journal Year:
2014,
Volume and Issue:
11(11), P. 1185 - 1200
Published: Jan. 1, 2014
Type
2
diabetes
is
a
serious
and
common
chronic
disease
resulting
from
complex
inheritance-environment
interaction
along
with
other
risk
factors
such
as
obesity
sedentary
lifestyle.Type
its
complications
constitute
major
worldwide
public
health
problem,
affecting
almost
all
populations
in
both
developed
developing
countries
high
rates
of
diabetes-related
morbidity
mortality.The
prevalence
type
has
been
increasing
exponentially,
rate
observed
undergoing
"westernization"
or
modernization.Multiple
diabetes,
delayed
diagnosis
until
micro-and
macro-vascular
arise,
life-threatening
complications,
failure
the
current
therapies,
financial
costs
for
treatment
this
disease,
make
it
necessary
to
develop
new
efficient
therapy
strategies
appropriate
prevention
measures
control
diabetes.Herein,
we
summarize
our
understanding
about
epidemiology
roles
genes,
lifestyle
contributing
rapid
increase
incidence
diabetes.The
core
aims
are
bring
forward
cost-effective
intervention
trials
diabetes.
Biomedicine & Pharmacotherapy,
Journal Year:
2020,
Volume and Issue:
131, P. 110708 - 110708
Published: Sept. 10, 2020
Diabetes
mellitus
(DM)
is
a
metabolic
disorder
that
occurs
in
the
body
because
of
decreased
insulin
activity
and/or
secretion.
Pathological
changes
such
as
nephropathy,
retinopathy,
and
cardiovascular
complications
inevitably
occur
with
progression
disease.
DM
mainly
categorized
into
2
sub-types,
type
I
II
DM.
While
generally
treated
through
replacement
therapy,
oral
hypoglycaemics.
The
major
drug
therapy
for
comprises
secretagogues,
biguanides,
sensitizers,
alpha
glucosidase
inhibitors,
incretin
mimetics,
amylin
antagonists
sodium-glucose
co-transporter-2
(SGLT2)
inhibitors.
Dual
therapies
are
often
recommended
patients
who
unable
to
achieve
therapeutic
goals
first
line
hypoglycaemic
agents
monotherapy.
Inspite
appreciable
benefits,
conventional
dosage
forms
depicts
differential
bioavailability
short
half-life,
mandating
frequent
causing
greater
side
effects
leading
ineffectiveness
patient
non-compliance.
Given
pathological
complexity
said
disease,
nanotechnology-based
approaches
more
enticing
it
comes
added
advantage
site-specific
delivery
higher
reduced
regimen.
In
present
review
article,
we
have
made
an
attempt
explore
pathophysiology
DM,
treatment
(mono
combination
therapy)
well
nano
based
Current Diabetes Reviews,
Journal Year:
2016,
Volume and Issue:
12(4), P. 359 - 368
Published: Oct. 26, 2016
The
World
Health
Organization
(WHO)
has
reported
that
Saudi
Arabia
ranks
the
second
highest
in
Middle
East,
and
is
seventh
world
for
rate
of
diabetes.
It
estimated
around
7
million
population
are
diabetic
almost
3
have
pre-diabetes.
Even
more
worrying
perhaps,
increasing
pattern
diabetes
noted
recent
past.
In
fact,
approximately
registered
a
ten-fold
increase
past
three
eras
Arabia.
Diabetes
mellitus
(DM)
been
found
to
be
related
high
mortality,
morbidity
vascular
complications,
accompanied
by
poor
general
health
lower
quality
life.
Arabia,
DM
quickly
reaching
disturbing
proportions
becoming
significant
cause
medical
complications
even
death.
However,
when
compared
with
developed
countries,
research
work
conducted,
focusing
particularly
on
incidence,
prevalence
socio-demographic
properties
woefully
inadequate.
burden
due
predicted
rise
catastrophic
levels,
unless
wide-ranging
epidemic
control
program
incorporated,
great
emphasis
laid
advocating
healthy
diet,
including
exercise
active
lifestyles,
weight
control.
To
properly
manage
multidisciplinary
approach
required.
this
review
we
discuss
all
aspects
drawing
from
published
literature
currently
available.
Advanced Healthcare Materials,
Journal Year:
2019,
Volume and Issue:
8(12)
Published: Jan. 15, 2019
Abstract
Nitric
oxide
(NO)
represents
a
potential
wound
therapeutic
agent
due
to
its
ability
regulate
inflammation
and
eradicate
bacterial
infections.
Two
broad
strategies
exist
utilize
NO
for
healing;
liberating
from
endogenous
reservoirs,
supplementing
exogenous
sources.
This
progress
report
examines
the
efficacy
of
variety
NO‐based
methods
improve
outcomes,
with
particular
attention
given
diabetes‐associated
chronic
wounds.
Journal of Enzyme Inhibition and Medicinal Chemistry,
Journal Year:
2017,
Volume and Issue:
32(1), P. 1216 - 1228
Published: Jan. 1, 2017
α-Glucosidase
inhibitors
are
described
as
the
most
effective
in
reducing
post-prandial
hyperglycaemia
(PPHG)
from
all
available
anti-diabetic
drugs
used
management
of
type
2
diabetes
mellitus.
As
flavonoids
promising
modulators
this
enzyme's
activity,
a
panel
44
flavonoids,
organised
five
groups,
was
screened
for
their
inhibitory
activity
α-glucosidase,
based
on
vitro
structure-activity
relationship
studies.
Inhibitory
kinetic
analysis
and
molecular
docking
calculations
were
also
applied
selected
compounds.
A
flavonoid
with
two
catechol
groups
A-
B-rings,
together
3-OH
group
at
C-ring,
active,
presenting
an
IC50
much
lower
than
one
found
widely
prescribed
α-glucosidase
inhibitor,
acarbose.
The
present
work
suggests
that
several
studied
have
potential
to
be
alternatives
regulation
PPHG.
Molecular Metabolism,
Journal Year:
2016,
Volume and Issue:
5(5), P. 317 - 320
Published: March 6, 2016
Like
all
healthy
ecosystems,
richness
of
microbiota
species
characterizes
the
GI
microbiome
in
individuals.
Conversely,
a
loss
diversity
is
common
finding
several
disease
states.
This
biome
flooded
with
energy
form
undigested
and
partially
digested
foods,
some
cases
drugs
dietary
supplements.
Each
microbiotic
transforms
that
into
new
molecules,
which
may
signal
messages
to
physiological
systems
host.
Dietary
choices
select
substrates
for
species,
providing
competitive
advantage
over
other
microbiota.
The
more
diverse
diet,
adaptable
it
will
be
perturbations.
Unfortunately,
has
been
lost
during
past
50
years
exclude
food
products
from
animals
or
plants
narrow
further.
Additional
research
expanding
gut
microbial
by
likely
expand
concepts
nutrition,
stimulate
discovery
diagnostics,
open
up
novel
therapeutic
possibilities.
